Last updated on April 23, 2014 at 1:22 EDT

Glysure CEO to Present Clinical Trial Updates at Fall Medtech Industry Conferences

September 25, 2012

ABINGDON, England, September 25, 2012 /PRNewswire/ –

GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems,
will update the industry on its progress toward U.S. and European regulatory trials at two
leading MedTech conferences this fall. GlySure CEO Christopher Jones will speak at the
AdvaMed 2012 MedTech Conference on October 2 in Boston, and at the Medical Devices Summit
Europe on November 14 in Dublin.

Tight Glycemic Control (TGC) in the Intensive Care Unit (ICU) has been shown to
improve outcomes, reduce mortality and cut the cost of care. GlySure recently conducted
human use trials that prove its system can continuously measure glucose levels across the
entire human physiological range with an extremely high degree of accuracy and
repeatability, which is key to effectively implementing TGC. The company is now preparing
for its European and U.S. clinical regulatory trials.

The Advanced Medical Technology Association (AdvaMed) has selected GlySure as one of
70 medical device companies to present at its annual conference, which is attended by
nearly 2,000 global MedTech executives, policy-makers, financiers, media and industry
stakeholders. At the event, Jones will present the results of GlySure’s latest clinical
trials and outline the company’s plans for CE and FDA regulatory trials in the coming

The producers of the 2012 Medical Devices Summit Europe have chosen Jones as one of 25
key MedTech leaders to share his insights on the global medical device industry. As a CEO
with experience running both U.S. and European device companies, Jones will discuss
“Strategies and Lessons Learned in International Distribution”.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a
proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for
implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).
The company has demonstrated through ICU testing highly accurate sensors, which can
provide continuous glucose readings throughout the length of a patient’s stay in the ICU.
GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20
employees. The company’s products are not approved for use in the U.S. or Europe.


Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127.

SOURCE GlySure Limited

Source: PR Newswire